Live price temporarily unavailable.
Carlisle Companies (CSL) is a Industrials company in the Russell 1000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.68B | $4.09B | $4.48B | $4.48B | $3.97B | $3.84B | $5.45B | $4.59B | $5.00B | $5.02B |
| Growth (year over year) | +3.7% | +11.3% | +9.5% | +0.1% | −11.5% | −3.4% | +42.0% | −15.8% | +9.1% | +0.3% |
| Gross profit | $1.16B | $1.05B | $1.17B | $1.37B | $1.14B | $1.10B | $1.87B | $1.63B | $1.89B | $1.79B |
| Gross margin | 31.5% | 25.6% | 26.2% | 30.6% | 28.7% | 28.6% | 34.2% | 35.6% | 37.7% | 35.7% |
| Operating income | $404.2M | $464.0M | $509.0M | $634.1M | $487.8M | $573.4M | $1.20B | $982.8M | $1.14B | $1.00B |
| Operating margin | 11.0% | 11.3% | 11.4% | 14.1% | 12.3% | 14.9% | 22.1% | 21.4% | 22.8% | 20.0% |
| Net income | $250.1M | $365.5M | $611.1M | $472.8M | $320.1M | $421.7M | $924.0M | $767.4M | $1.31B | $740.7M |
| Net margin | 6.8% | 8.9% | 13.6% | 10.5% | 8.1% | 11.0% | 17.0% | 16.7% | 26.2% | 14.8% |
| EPS (diluted) | $3.82 | $5.71 | $10.02 | $8.19 | $5.80 | $7.91 | $17.56 | $15.18 | $27.82 | $17.12 |
| Balance sheet | ||||||||||
| Cash and equivalents | $385.0M | $378.3M | $803.6M | $351.2M | $897.1M | $324.4M | $364.8M | $576.7M | $753.5M | $1.11B |
| Total assets | $3.97B | $5.30B | $5.25B | $5.50B | $5.87B | $7.25B | $7.22B | $6.62B | $5.82B | $6.26B |
| Total liabilities | $1.50B | $2.77B | $2.65B | $2.85B | $3.33B | $4.62B | $4.20B | $3.79B | $3.35B | $4.47B |
| Long-term debt | $596.4M | $1.59B | $1.59B | $1.34B | $2.08B | $2.58B | $2.28B | $1.89B | $1.89B | $2.88B |
| Shareholders' equity | $2.47B | $2.53B | $2.60B | $2.64B | $2.54B | $2.63B | $3.02B | $2.83B | $2.46B | $1.80B |
| Cash flow | ||||||||||
| Operating cash flow | $531.2M | $458.7M | $339.2M | $703.1M | $696.7M | $421.7M | $1.00B | $1.20B | $1.03B | $1.10B |
| Capital expenditure | $108.8M | $159.9M | $120.7M | $88.9M | $95.5M | $134.8M | $183.5M | $142.2M | $113.3M | $131.2M |
| Free cash flow | $422.4M | $298.8M | $218.5M | $614.2M | $601.2M | $286.9M | $817.4M | $1.06B | $917.0M | $970.6M |
| Dividends paid | $84.5M | $92.1M | $93.5M | $102.9M | $112.4M | $112.5M | $134.4M | $160.3M | $172.4M | $181.1M |
| Share buybacks | $75.0M | $268.4M | $459.8M | $382.1M | $382.4M | $315.6M | $400.0M | $900.0M | $1.59B | $1.30B |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.33B | $1.12B | $1.10B | $1.45B | $1.35B | $1.13B | $1.05B | $1.57B |
| Growth (year over year) | +5.9% | −0.4% | −0.1% | −0.1% | +1.0% | +0.4% | −4.0% | +8.3% |
| Gross profit | $514.4M | $405.5M | $385.7M | $541.1M | $485.2M | $380.6M | $363.2M | $568.4M |
| Gross margin | 38.6% | 36.1% | 35.2% | 37.3% | 36.0% | 33.8% | 34.5% | 36.2% |
| Operating income | $316.4M | $224.0M | $183.6M | $335.0M | $293.9M | $190.0M | $180.3M | $352.5M |
| Operating margin | 23.7% | 19.9% | 16.8% | 23.1% | 21.8% | 16.8% | 17.1% | 22.4% |
| Net income | $244.3M | $162.8M | $143.3M | $255.8M | $214.2M | $127.4M | $127.7M | $255.2M |
| Net margin | 18.3% | 14.5% | 13.1% | 17.6% | 15.9% | 11.3% | 12.1% | 16.3% |
| EPS (diluted) | $5.25 | $3.76 | $3.20 | $5.88 | $4.98 | $3.06 | $3.10 | $6.30 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.53B | $753.5M | $220.2M | $68.4M | $1.10B | $1.11B | $771.3M | $665.3M |
| Total assets | $6.48B | $5.82B | $5.45B | $5.52B | $6.46B | $6.26B | $5.99B | $6.23B |
| Total liabilities | $3.72B | $3.35B | $3.28B | $3.40B | $4.46B | $4.47B | $4.34B | $4.62B |
| Long-term debt | $1.89B | $1.89B | $1.89B | $1.89B | $2.88B | $2.88B | $2.88B | $2.88B |
| Shareholders' equity | $2.76B | $2.46B | $2.17B | $2.12B | $1.99B | $1.80B | $1.65B | $1.62B |
| Cash flow | ||||||||
| Operating cash flow | $312.8M | $370.6M | $1.80M | $287.1M | $426.9M | $386.0M | −$44.7M | $241.8M |
| Capital expenditure | $19.3M | $36.6M | $29.0M | $28.8M | $33.5M | $39.9M | $28.3M | $41.7M |
| Free cash flow | $293.5M | $334.0M | −$27.2M | $258.3M | $393.4M | $346.1M | −$73.0M | $200.1M |
| Dividends paid | $45.7M | $45.0M | $45.2M | $43.1M | $47.0M | $45.8M | $45.7M | $44.4M |
| Share buybacks | $466.1M | $419.8M | $400.0M | $300.0M | $300.0M | $300.0M | $250.0M | $250.0M |
From Carlisle Companies's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Carlisle Companies Incorporated is a supplier of construction products that make buildings more energy efficient and resilient. The company manufactures and sells single-ply roofing products as well as warranted systems and accessories for the commercial building industry. The company is organized into two segments, including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.
Source: Wikipedia — Carlisle Companies
CSL to pay up to $1.6 bln to develop rare disease drug; shares rise
CSL to pay up to $1.6 bln to develop rare disease drug; shares rise